MarketPulse

osteoporosis

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Teva Pharmaceutical Industries Ltd.

Teva Scales Biosimilars Pipeline with FDA Approval of PONLIMSI, Xolair Candidate Filing

Teva gains FDA approval for denosumab biosimilar PONLIMSI and achieves dual filing acceptance for omalizumab candidate, bolstering its biosimilars portfolio.
AMGNNVSTEVAFDA approvalbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva Gains Biosimilar Momentum With FDA Approval, Dual Regulatory Filings

Teva wins FDA approval for PONLIMSI biosimilar and dual regulatory filing acceptance for omalizumab biosimilar, advancing its 'Pivot to Growth' strategy.
AMGNNVSTEVAFDA approvalregulatory filing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Teva Advances Biosimilar Pipeline With FDA Approval of PONLIMSI and Xolair Candidate

Teva gains FDA approval for PONLIMSI denosumab biosimilar and dual regulatory acceptance for omalizumab candidate, advancing biosimilar growth strategy.
AMGNNVSTEVAFDA approvalpharmaceutical